Moderna

YTD

ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.

CEO

Stéphane Bancel

CEOStéphane Bancel

Employees

4,700

Employees4,700

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2010

Founded2010

Employees

4,700

Employees4,700

MRNA Key Statistics

Market cap

19.43B

Market cap19.43B

Price-Earnings ratio

-6.89

Price-Earnings ratio-6.89

Dividend yield

—

Dividend yield—

Average volume

6.75M

Average volume6.75M

High today

$50.51

High today$50.51

Low today

$48.11

Low today$48.11

Open price

$48.36

Open price$48.36

Volume

4.63M

Volume4.63M

52 Week high

$59.55

52 Week high$59.55

52 Week low

$22.28

52 Week low$22.28

Stock Snapshot

With a market cap of 19.43B, Moderna(MRNA) trades at $49.32. The stock has a price-to-earnings ratio of -6.89.

On 2026-04-02, Moderna(MRNA) stock traded between a low of $48.11 and a high of $50.51. Shares are currently priced at $49.32, which is +2.5% above the low and -2.4% below the high.

Moderna(MRNA) shares are trading with a volume of 4.63M, against a daily average of 6.75M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $59.55 and a 52-week low of $22.28.

MRNA News

Simply Wall St 4h

Why Moderna Is Down 6.6% After Its ‘Moderna 2.0’ Cancer-Vaccine Pivot - And What's Next

In late March 2026, Moderna participated in the World Vaccine Congress Washington and the 4th annual Entrepreneurship Summit, where senior leaders highlighted i...

Simply Wall St 1d

Moderna Valuation Check As Moderna 2.0 Oncology Pivot And Legal Settlement Shift Expectations

Moderna (MRNA) is back in focus after leadership promoted its so called Moderna 2.0 pivot toward oncology and individualized cancer therapy, paired with a multi...

Nasdaq 1d

Strength Seen in Rhythm Pharmaceuticals: Can Its 12.6% Jump Turn into More Strength?

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 12.6% in the last trading session to close at $86.97. This move can be attributable to notable volume with a...

Analyst ratings

69%

of 26 ratings

Buy

15.4%

Hold

69.2%

Sell

15.4%

More MRNA News

TipRanks 1d

Moderna price target raised to $48 from $25 at Barclays

Barclays raised the firm’s price target on Moderna (MRNA) to $48 from $25 and keeps an Equal Weight rating on the shares. Unlock hedge fund-level data and powe...

Simply Wall St 6d

Moderna Faces EMA Approval And FDA Pushback As Valuation Risks Mount

Moderna (NasdaqGS:MRNA) has received European Medicines Agency approval for its mRNA flu vaccine, following efficacy data in older adults. In the U.S., the FDA...

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.